|
19 December 2006
EPO Announces European Nexium® Substance Patent Decision |
AstraZeneca today announced that the European Patent Office (EPO) has ruled that one of the European substance patents for Nexium® (EP 0652872) will be rejected, following an appeal from the German generic manufacturer Ratiopharm. The original patent expiry for this patent was 2014.
|
 |
11 December 2006
Egyptian Health Minister Opens AstraZeneca’s New $32M Manufacturing Plant near Cairo |
Egyptian Health Minister Dr. Hatem Mostafa El-Gabaly today opened a new $32 million tablet factory built by AstraZeneca near Cairo – the company’s first manufacturing investment in the Middle East. David Brennan, Chief Executive Officer of AstraZeneca, also attended the opening ceremony at the factory in 6th of October City.
|
|
5 December 2006
AstraZeneca Commitment To China Recognised by Cathay Pacific Award |
AstraZeneca was today named one of three winners of the Cathay Pacific Awards for its outstanding and continued commitment to China.
In recent years AstraZeneca has become the leading multinational pharmaceutical company in China in prescription sales, has established 25 sales offices in major cities across the country, created a $134m state-of-the-art manufacturing facility in Wuxi, Jiang Su Province, and has committed a further $100m to Research and Development.
|
|
4 December 2006
AstraZeneca Licenses Rights for the Development and Commercialisation of CUBICIN® in China |
|
|
22 November 2006
AstraZeneca signs distribution agreement with Par Pharmaceutical for an authorized generic version of TOPROL-XL |
AstraZeneca today announced it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of metoprolol succinate in the United States. Currently, the authorized generic product will be distributed in the 25 mg dosage strength. The signing of this agreement does not affect the availability of AstraZeneca’s branded version of metoprolol succinate, TOPROL-XL. AstraZeneca will continue to manufacture and make TOPROL-XL available in the United States.
|
|
3 November 2006
AstraZeneca Updates CytoFab™ Development Programme |
AstraZeneca today announced its intention to expand the development plan for CytoFab™, a treatment for severe sepsis, with the addition of a 480 - patient Phase II study programme.
|
|
26 October 2006
Third Quarter and Nine Months Results 2006 |
"A strong third quarter with sales up 11 percent and Earnings per Share up 34 percent."
 Download the narrative and the figures
|
|
26 October 2006
AstraZeneca Announces SAINT II Trial Results Showed No Efficacy in Acute Ischaemic Stroke |
Results from the SAINT II (Stroke Acute Ischemic NXY-059 Treatment) trial, announced today by AstraZeneca, showed that the investigational drug NXY-059 did not meet its primary outcome of a statistically significant reduction in stroke-related disability, as assessed by the modified Rankin Scale (mRS) (p=0.33, odds ratio 0.94) compared to placebo.
|
|
20 October 2006
FDA Approves AstraZeneca’s SEROQUEL® for Bipolar Depression Treatment |
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is now the first and only single medication approved by the FDA to treat both depressive and manic episodes associated with bipolar disorder.
|
|
19 October 2006
AstraZeneca Submits EU and Canadian Regulatory Filings for Sustained Release Formulation SEROQUEL SR™ for the Treatment of Schizophrenia |
AstraZeneca today announced further submissions to Regulatory Authorities for the approval of the sustained release (SR) once-daily formulation of SEROQUEL® for the treatment of patients with schizophrenia, including Canada and a Marketing Authorisation Application (MAA) in the European Union (EU) under Mutual Recognition Procedure (MRP). The submission will cover all markets in the EU where SEROQUEL® is currently approved.
|
|
9 October 2006
AstraZeneca Successfully Completes Mutual Recognition Procedure For Symbicort® Maintenance And Reliever Therapy (Symbicort SMART®) in the EU |
AstraZeneca today announced that it has successfully completed the European Union Mutual Recognition Procedure (MRP) for Symbicort® Maintenance And Reliever Therapy (Symbicort SMART®). This new treatment approach enables patients to take control of their asthma and use just one inhaler for both maintenance and relief of asthma symptoms.
|
|
18 September 2006
AstraZeneca Officially Opens Two Major Scientific Laboratories, As Latest Phase Of UK R&D Investment Programme |
AstraZeneca announces the official opening this week of two major scientific laboratories in the UK. These latest developments add to AstraZeneca’s significant investment in the UK, with the creation of over 550 new science-related jobs over the last seven years.
|
|
15 September 2006
AstraZeneca and Schering AG Form Strategic Alliance to Develop Novel SERD Breast Cancer Drug |
AstraZeneca and Schering AG, Germany (FSE: SCH, NYSE: SHR) have formed a new alliance to co-develop and jointly commercialise Schering AG’s novel SERD (selective estrogen receptor downregulator) to treat breast cancer.
|
|
22 August 2006
AstraZeneca UK Limited Completes Acquisition of Cambridge Antibody Technology Group plc Compulsory Acquisition Procedure Completed Subsequent Offer Period Closed |
AstraZeneca today announced that it has completed the compulsory acquisition procedure under the Interim Regulations and now owns 100 percent of the issued share capital of CAT.
|
|
2 August 2006
AstraZeneca and Pozen Inc Sign Deal to Develop and Commercialise naproxen and esomeprazole Fixed Dose Combinations utilising Pozen’s Proprietary Technology for the Treatment of Chronic Pain |
AstraZeneca today announced an exclusive global agreement with Pozen Inc. (NASDAQ: POZN) to co-develop fixed dose combinations of naproxen and esomeprazole for chronic pain, utilising Pozen’s proprietary formulation technology. The fixed dose combinations have the potential to provide chronic pain sufferers with a new treatment with good efficacy and a low upper gastro-intestinal (GI) side-effect profile.
|
|
27 July 2006
Second Quarter and Half Year Results 2006 |
"A strong second quarter, with sales up 10 percent and Earnings per Share up 41 percent; on track to achieve financial targets for the full year."
|
|
26 July 2006
AstraZeneca PLC appoints new Non-Executive Director |
AstraZeneca today announced that John Varley is to join the Board of Directors as a Non-Executive Director with immediate effect. John Varley is the Group Chief Executive of Barclays Bank PLC. Louis Schweitzer, Chairman of AstraZeneca, said, “I am delighted that John Varley has agreed to join us. His extensive commercial and financial expertise will add considerable benefit to the work of the Board”.
|
|
22 July 2006
AstraZeneca’s SYMBICORT® (budesonide/formoterol) Treatment For Asthma Approved By The FDA |
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBICORT® (budesonide/formoterol) for the maintenance treatment of asthma in patients age 12 and older.
|
|
18 July 2006
AstraZeneca Submits an NDA For Sustained Release Formulation SEROQUEL SR(TM) For the Treatment of Schizophrenia |
AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. The clinical trials to support the US submission of SEROQUEL SRTM used a short titration period aimed at achieving a therapeutically effective dose by the second day of treatment. The Company also expects to make a SEROQUEL SRTM filing in the European Union towards the end of 2006. The SR formulation has patent protection to 2017.
|
|
7 July 2006
Recommended Cash Offer by AstraZeneca UK Limited for Cambridge Antibody Technology Group plc Posting of Compulsory Acquisition Notices |
|
|
5 July 2006
AstraZeneca And Abbott To Co-Develop And Co-Market A Single-Pill, Fixed-Dose Combination Of CRESTOR® And Next-Generation TriCor ® (ABT-335) In The United States |
AstraZeneca and Abbott announced today a collaboration to co-develop and market a combination treatment that will target three important blood lipids - LDL ("bad" cholesterol), HDL ("good" cholesterol), and triglycerides – in one single pill as part of a comprehensive treatment regimen for mixed lipid disorders.
|
|
30 June 2006
Recommended Cash Offer by AstraZeneca UK Limited for Cambridge Antibody Technology Group plc Initial Offer Period Closed Subsequent Offer Period Commenced |
|
|
28 June 2006
Addition of budesonide to formoterol (Symbicort®) and/or a short-acting beta 2 agonist reduces the risk of mortality in patients with severe COPD compared to bronchodilators alone |
Important new data from the analysis of combined data from the two pivotal Symbicort® studies, announced today at the 5th International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5) in Birmingham, reveals that budesonide added to formoterol (Symbicort®) and/or terbutaline, significantly reduces mortality in severe COPD over one year, compared to the bronchodilators formoterol and/or terbutaline alone.
|
|
22 June 2006
Recommended Cash Offer by AstraZeneca UK Limited for Cambridge Antibody Technology Group plc Offer Declared Unconditional and Initial Offer Period Extended |
AstraZeneca announces that it has acquired, or received valid acceptances of the Offer in respect of, 37,261,730 CAT Shares in aggregate, representing approximately 86.7 per cent. of the CAT Shares to which the Offer relates
|
|
19 June 2006
Biggest LDL-C Reduction Ever Shown In Patients Is Achieved With A CRESTOR Combination Therapy |
New study results offer hope as an important treatment option
for difficult-to-treat patients
A combination treatment regimen of CRESTORTM (rosuvastatin) 40 mg and ezetimibe 10 mg achieved an unprecedented 70 per cent reduction in LDL-C which is the largest reduction in LDL-C ever seen in a statin clinical trial. In just six weeks, this combination treatment also helped more high-risk patients (94 per cent) – whose LDL-C needs to be reduced to less than 100mg/dL– achieve their guideline LDL-C goals than those treated with CRESTOR alone (79 per cent ) (p<0.001). These results from the EXPLORER study will be presented for the first time this week at the International Symposium on Atherosclerosis.
|
|
8 June 2006
AstraZeneca Outlines Strategy to Further Strengthen Its Product Pipeline While Delivering Continued Sales and Earnings Growth |
AstraZeneca will provide an update on its strategy and development pipeline through to the end of the decade at a business review meeting to be held in London today.
|
|
26 May 2006
AstraZeneca Announces $100 Million R&D Investment in China |
New Innovation Centre to Focus Initially on Oncology Research
AstraZeneca today announced its intention to invest $100 million in R&D in China over the next three years, focusing on the benefit and value of innovative medicines for Chinese patients.
|
|
15 May 2006
AstraZeneca's recommended offer for Cambridge Antibody Technology |
Please click here for the full press release
|
|
4 May 2006
AstraZeneca Discontinues Development of GALIDA TM (tesaglitazar) |
AstraZeneca today announced the discontinuation of the GALIDA development programme. GALIDA is a dual PPAR alpha and gamma agonist and was in phase III development for the treatment of the glucose and lipid abnormalities associated with type 2 diabetes.
|
|
27 April 2006
First quarter results 2006 |
"A strong first quarter, with sales up 12 percent and Earnings per Share up 40 percent. Targets for the full year increased."
|
|
27 April 2006
AstraZeneca and Abraxis BioScience to co-promote cancer therapy ABRAXANE; Abraxis BioScience to acquire AstraZeneca’s U.S Anaesthetic and Analgesic Product Portfolio |
AstraZeneca today announced an agreement with Abraxis BioScience Inc. (ABBI) to co-promote ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. In addition to the co-promotion agreement for ABRAXANE®, AstraZeneca also announced the divestment of its US anaesthetics and analgesic products to Abraxis BioScience.
|
|
28 March 2006
London Stock Exchange Announcement: AstraZeneca PLC Annual Information Update |
As required under the Prospectus (Directive 2003/71/EC) Regulations 2005 and paragraph 5.2 of the Prospectus Rules, and following publication of the Annual Report and Form 20-F Information on 28 February 2006, AstraZeneca PLC is presenting its first Annual Information Update in relation to information that has been published or made available to the public between 1 February 2005 and 27 March 2006.
|
|
20 March 2006
London Stock Exchange Announcement: Notice Of Annual General Meeting 2006 And Proposed Board Changes |
AstraZeneca PLC announced today the publication of its Notice of Annual General Meeting for 2006 with a covering letter from the Chairman of the Board, and a Shareholders’ Circular and Proxy Form.
|
|
14 March 2006
AstraZeneca Education Seminar on Merck arrangements |
On Tuesday, 14 March 2006 at 13:00GMT (14:00CET, 08:00EST) AstraZeneca will conduct an education seminar on the topic of the Company’s arrangements with Merck. Details for accessing the audio webcast of this seminar are listed below.
|
|
14 March 2006
Headline Results From Chant Safety and Tolerability Study In Intracerebral Hemorrhage (Ich) Show NXY-059 Achieved Key Endpoints |
AstraZeneca today announced results from the phase IIb safety and tolerability trial for NXY-059 in acute intracerebral hemorrhage (ICH) patients, CHANT (Cerebral Hemorrhagic And NXY-059 Treatment). Although AstraZeneca is developing NXY-059 for the treatment of Acute Ischemic Stroke (AIS), it was felt important to assess the safety and tolerability of NXY-059 in ICH, as treatment may be initiated prior to a neuroimaging confirmation of the diagnosis of AIS. The data showed that the safety and tolerability of NXY-059 in ICH patients was similar to placebo, with comparable mortality rates (20% in each group) and there was no difference seen between the NXY-059 and placebo groups on the secondary endpoint of stroke outcomes in the study.
|
|
13 March 2006
First Statin To Show Regression Of Coronary Artery Disease In A Major Clinical Study |
ASTEROID studied the effect of intensive CRESTOR therapy on reversal of atherosclerosis
|
|
13 March 2006
LSE Announcement: Crestor Shows Regression of Coronary Artery Disease in a Major Clinical Study |
|
|
9 March 2006
AstraZeneca commences patent infringement litigation against IVAX |
AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals, Inc. and Zenith Laboratories, Inc. (collectively “IVAX”), and IVAX’s parent, Teva Pharmaceutical Industries Ltd. and its U.S. subsidiary, Teva Pharmaceuticals USA, for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium).
|
|
28 February 2006
AstraZeneca Issues 2005 Annual Report |
AstraZeneca today published its 2005 Annual Report and Form 20-F Information, its 2005 Annual Review and its 2005 Corporate Responsibility Summary Report. These documents are available on the company’s website, www.astrazeneca.com/annualreport
|
|
16 February 2006
AstraZeneca Files Notice Of Appeal For Patent Infringement On Toprol-XL® |
AstraZeneca announced today that is has filed a Notice with the US District Court for the Eastern District of Missouri of its appeal to the Court of Appeals for the Federal Circuit of the January 17, 2006 decision by Judge Rodney Sippel declaring US compound patent Number 5,081,154 and composition patent Number 5,001,161 covering TOPROL XL (metoprolol succinate) extended release tablets invalid and unenforceable.
|
|
14 February 2006
AstraZeneca Decides to Withdraw Exanta™ |
Patients must not stop taking their tablets without speaking to their doctor.
AstraZeneca today announced that the company has decided to withdraw the anticoagulant Exanta™ (melagatran / ximelagatran) from the market and terminate its development. AstraZeneca estimates that approximately 400 patients are currently being prescribed the drug for short-term prevention of venous thromboembolism (VTE) following orthopaedic surgery (OS). Two ongoing Exanta clinical trials will be discontinued and Exanta-treated patients switched to other treatments. It is important that patients do not stop Exanta treatment without consulting their doctor. Regulatory files in OS and other indications in the US, Europe and elsewhere will now be withdrawn.
|
|
2 February 2006
Fourth Quarter and Full Year Results 2005 |
"Strong growth from key products and improved efficiency drive 44 percent increase in Earnings per Share for 2005."
AstraZeneca PLC Fourth Quarter and Full Year Results 2005
|
|
18 January 2006
Toprol-XL® (metoprolol succinate): AstraZeneca to Appeal Decision in U.S. Patent Litigation
|
AstraZeneca today announced that it has received a decision of Judge Rodney Sippel of the U.S. District Court for the Eastern District of Missouri in litigation titled In Re Metoprolol Succinate Patent Litigation. This case is a consolidation of the company’s cases against defendants KV Pharmaceutical Company, Andrx Pharmaceuticals LLC, Andrx Corporation, and Eon Labs Manufacturing, Inc. The decision was issued in response to motions by all parties argued on November 16-17, 2005, regarding the validity, enforceability and infringement of two of the U.S. patents associated with TOPROL-XL® (metoprolol succinate) extended release tablets.
|
|
3 January 2006
AstraZeneca Submits sNDA For Seroquel For Bipolar Depression Treatment
|
Filing Seeks Approval of SEROQUEL as a Monotherapy Treatment for Bipolar Depression
|
|